Frontier Medicines focuses on developing precision medicines for genetically-defined patient populations to deliver maximal benefit, utilizing proprietary platforms powered by chemoproteomics, covalent chemistry, and machine learning.

Frontier Medicines

IPhone / Mobile Compatible

Viewport Meta

Domain Not Resolving

Google Tag Manager

Google Maps

Typekit

Mobile Optimized

Drupal

Add to Any

Drupal 10

Co-Founder, Chairman & CEO

Chris Varma

Chief Technology Officer

Johannes Hermann

Chief Science Officer

Kevin Webster

Chief People & Culture Officer

Monique Bobadilla

Senior Vice President, Head of Business Development

Christo Shalish

Finance and Administration

Tina Gullotta

Marketing and Product

Victoria Fort

Engineering

Alessandra Ianari

Associate Director

Barun Bhhatarai

Christian Kjaergaard

Derek DiRocco

Othman Laraki

Founder, President & CEO

Gerardo Ubaghs Carrión

Chief Financial Officer

Vice President Finance

Andrew Krivoshik

Chief Medical Officer

Daniel A. Erlanson

VP of Chemistry

Daniel Nomura

Co-Founder and Scientific Adviser

West Coast Late Stage Companies With Less Than $500M in Revenue

United States Startups Founded in 2018

San Francisco Bay Area Late Stage Companies

Western US Companies With Less Than $1B in Revenue (Top 10K)

Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines. Its platform integrates advanced computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins that make them accessible to small-molecule drug discovery and development.

Series C - Frontier Medicines

Deerfield Management

Droia Ventures

RA Capital Management

Woodline Partners

Series B - Frontier Medicines

Deerfield

MPM Capital

Series A - Frontier Medicines

San Francisco

California

United States

North America

Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor

Frontier Medicines divulges new GTPase KRAS mutant inhibitors

Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension

Fierce Biotech Fundraising Tracker 2024

AACR: KRAS inhibitors pop in preclinical data debuts

Philippines

Asia

Belgium

Europe

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Sep 26, 2024 2:07 PM	98ac4559
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general	Sep 26, 2024 2:07 PM	de1ab23a
news processing advanced	general
crunchbase trigger	general	Oct 29, 2024 5:10 PM	409b5e20
crunchbase profile	general	Oct 30, 2024 6:45 AM	e8d5917c
li profile	general
translate crunchbase fundingrounds	general
peers	general	Sep 26, 2024 2:07 PM	40d095f4
news basic	general	Sep 26, 2024 2:07 PM	3c921a7d
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:FRONTIERMEDS

Frontier Medicines